First in Human Study of AZD9592 in solid tumors - EGRET

Study identifier:D9350C00001

ClinicalTrials.gov identifier:NCT05647122

EudraCT identifier:N/A

CTIS identifier:2022-501570-18-00

Recruiting

Official Title

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

Medical condition

Advanced Solid Tumours

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab

Sex

All

Estimated Enrollment

108

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 22 Dec 2022
Estimated Primary Completion Date: 29 Oct 2025
Estimated Study Completion Date: 29 Oct 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria